Literature DB >> 25564771

Nonalcoholic fatty liver disease: Fibrosis portends a worse prognosis.

Dawn M Torres1, Stephen A Harrison.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25564771     DOI： 10.1002/hep.27680

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  6 in total

1.  Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.

Authors:  Michele Malaguarnera; Massimo Motta; Marco Vacante; Giulia Malaguarnera; Filippo Caraci; Giuseppe Nunnari; Caterina Gagliano; Carmela Greco; Giuseppe Chisari; Filippo Drago; Gaetano Bertino
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

2.  NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.

Authors:  Auvro R Mridha; Alexander Wree; Avril A B Robertson; Matthew M Yeh; Casey D Johnson; Derrick M Van Rooyen; Fahrettin Haczeyni; Narci C-H Teoh; Christopher Savard; George N Ioannou; Seth L Masters; Kate Schroder; Matthew A Cooper; Ariel E Feldstein; Geoffrey C Farrell
Journal:  J Hepatol       Date:  2017-02-03       Impact factor: 25.083

3.  Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China.

Authors:  Yuying Wang; Yuetian Yu; Haojie Zhang; Chi Chen; Heng Wan; Yi Chen; Fangzhen Xia; Shiyan Yu; Ningjian Wang; Lin Ye; Yingli Lu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-02       Impact factor: 6.055

4.  Epigenetic Modifications in the Biology of Nonalcoholic Fatty Liver Disease: The Role of DNA Hydroxymethylation and TET Proteins.

Authors:  Carlos J Pirola; Romina Scian; Tomas Fernández Gianotti; Hernán Dopazo; Cristian Rohr; Julio San Martino; Gustavo O Castaño; Silvia Sookoian
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

5.  The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.

Authors:  Rohit Loomba; Eric Lawitz; Parvez S Mantry; Saumya Jayakumar; Stephen H Caldwell; Hays Arnold; Anna Mae Diehl; C Stephen Djedjos; Ling Han; Robert P Myers; G Mani Subramanian; John G McHutchison; Zachary D Goodman; Nezam H Afdhal; Michael R Charlton
Journal:  Hepatology       Date:  2017-12-26       Impact factor: 17.425

Review 6.  Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders.

Authors:  Andrey Turchinovich; Ancha Baranova; Oksana Drapkina; Alexander Tonevitsky
Journal:  Front Physiol       Date:  2018-09-20       Impact factor: 4.566
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.